261 related articles for article (PubMed ID: 28529576)
1. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.
Wang B; Jiang H; Wang L; Chen X; Wu K; Zhang S; Ma S; Xia B
Oncol Lett; 2017 May; 13(5):3494-3500. PubMed ID: 28529576
[TBL] [Abstract][Full Text] [Related]
2. Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway.
Deng QF; Su BO; Zhao YM; Tang L; Zhang J; Zhou CC
Oncol Lett; 2016 Jan; 11(1):535-542. PubMed ID: 26870244
[TBL] [Abstract][Full Text] [Related]
3. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
[TBL] [Abstract][Full Text] [Related]
5. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
6. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
Wang J; He X; Jia Z; Yan A; Xiao K; Liu S; Hou M; Long Y; Ding X
Pharm Biol; 2024 Dec; 62(1):33-41. PubMed ID: 38100532
[TBL] [Abstract][Full Text] [Related]
7. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Wan Y; Yuan Y; Pan Y; Zhang Y
Exp Ther Med; 2017 Jun; 13(6):3067-3074. PubMed ID: 28587381
[TBL] [Abstract][Full Text] [Related]
9. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
[TBL] [Abstract][Full Text] [Related]
10. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines].
Fang X; Gu P; Zhou CC; Ren SX; Luo BF; Zeng Y; Wu YJ; Zhao YM; Zhu XY; Yi XH
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):455-9. PubMed ID: 24246864
[TBL] [Abstract][Full Text] [Related]
13. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Deng QF; Su B; Zhao YM; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
[TBL] [Abstract][Full Text] [Related]
14. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
15. Effects of miR-143 overexpression on proliferation, apoptosis, EGFR and downstream signaling pathways in PC9/GR cell line.
Dong YZ; Hu T
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1709-1716. PubMed ID: 29630116
[TBL] [Abstract][Full Text] [Related]
16. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer.
Chen J; Shi L; Qian Y; Jin Y; Dong N; Chen C; Wang B
J Thorac Dis; 2023 Jun; 15(6):3359-3371. PubMed ID: 37426126
[TBL] [Abstract][Full Text] [Related]
18. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
19. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Yang B; Yang ZG; Gao B; Shao GG; Li GH
Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44.
Wang H; Lu B; Ren S; Wu F; Wang X; Yan C; Wang Z
Mol Ther Nucleic Acids; 2020 Mar; 19():218-227. PubMed ID: 31841994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
